Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
| Author | |
|---|---|
| Abstract | :
Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated. |
| Year of Publication | :
2018
|
| Journal | :
Alimentary pharmacology & therapeutics
|
| Date Published | :
2018
|
| ISSN Number | :
0269-2813
|
| URL | :
http://dx.doi.org/10.1111/apt.14514
|
| DOI | :
10.1111/apt.14514
|
| Short Title | :
Aliment Pharmacol Ther
|
| Download citation |